Sodium oxybate-induced central sleep apneas

详细信息    查看全文

• 作者：Lukas Frase ; Jonas Schupp ; Stephan Sorichter ; Wolfgang R ; elshofer ; Dieter Riemann ; Christoph Nissen
• 关键词：Sleep ; Narcolepsy ; Sodium oxybate ; Xyrem ; Cataplexy ; Central sleep apnea ; Cheyne&ndash ; Stokes respiration
• 刊名：Sleep Medicine
• 出版年：2013
• 出版时间：September, 2013
• 年：2013
• 卷：14
• 期：9
• 页码：922-924
• 全文大小：1040 K

文摘

Sodium oxybate (¦Ã-hydroxybutyric acid, GHB) is a neurotransmitter in the human brain which exerts sedative effects and is used therapeutically in the treatment of narcolepsy. Current safety recommendations have been formulated for the use of GHB in patients with preexisting breathing disorders. We report the case of a 39-year-old female with narcolepsy and cataplexy revealing the de novo emergence of central sleep apneas in a Cheyne-Stokes pattern under constant treatment with GHB. After discontinuation of GHB, polysomnographic re-evaluation demonstrated the disappearance of central sleep apneas. To our knowledge, this is the first report of de novo central sleep apneas induced by GHB in a patient without pre-existing sleep-disordered breathing, suggesting that there is a need for further investigation and potentially an extension of the safety guidelines to patients without a pre-existing breathing disorder.